A Phase 3 interventional study of Fulvestrant and Capivasertib in Locally Advanced (Inoperable) or Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 215 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing capivasertib in Breast Neoplasms — 3 open to participants now, 13 under way, 7 of them phase 3. capivasertib · Breast Neoplasms.
Among the 20 studies testing capivasertib in Breast Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, reaches primary completion later than 2 of the 12 other live ones, and was the 12th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →3 of the 20 studies testing capivasertib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Women's Cancer Study Group GmbH · Sites in Belgium, Germany, Portugal
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Women only
SWOG Cancer Research Network
Ages 18+
By country, each count listing its studies:
capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, capivasertib is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 818 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 247 across the 20 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 20 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 18th largest by enrollment of the 125 interventional ones that give a count, is one of 11 that started in 2020, is one of 46 in phase 3, reaches primary completion later than 3 of the 49 other live ones, and was the 127th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
2 of the studies testing capivasertib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04862663Phase 3AstraZenecaCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | 2027-11-01 |
| NCT06764186Phase 3AstraZenecaA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing capivasertib in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.
Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are to have received treatment with an AI (aromatase inhibitor) containing regimen (single agent or in combination) and have:
Exclusion Criteria:
Prior treatment with any of the following:
Any of the following cardiac criteria:
Clinically significant abnormalities of glucose metabolism as defined by any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.
Drug: Fulvestrant · Drug: Capivasertib
Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.
Drug: Fulvestrant · Drug: Placebo
Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Progression Free Survival: Overall Population (Months) in the Global Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Participants who discontinue treatment prior to progression should continue to be scanned until progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s).
Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Progression Free Survival: Overall Population (Percentage) in the Global Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.
Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Progression Free Survival: Altered Population (Months) in the Global Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.
Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Progression Free Survival: Altered Population (Percentage) in the Global Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Kaplan-Meier estimate was used.
Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Progression Free Survival: Overall Population (Months) in the China Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression.
Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Progression Free Survival: Overall Population (Percentage) in the China Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.
Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Progression Free Survival: Altered Population (Months) in the China Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.
Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Progression Free Survival: Altered Population (Percentage) in the China Cohort
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause Kaplan-Meier estimate was used.
Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
A total of 708 participants in Global cohort (out of 818 participants in Global and China cohorts) were randomized to treatment. An additional 110 participants were enrolled into the China cohort only.
| Milestone | Capivasertib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Started | 355 | 353 |
| Completed | 63 | 43 |
| Not completed | 292 | 310 |
| Withdrew: Withdrawal by subject | 13 | 6 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Subjective disease progression | 16 | 17 |
| Withdrew: Condition under investigation worsened | 209 | 273 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Adverse event | 44 | 6 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Any reason not specifically recorded | 4 | 5 |
| Milestone | Capivasertib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Started | 71 | 63 |
| Completed | 18 | 10 |
| Not completed | 53 | 53 |
| Withdrew: Any reason not specifically recorded | 1 | 1 |
| Withdrew: Adverse event | 8 | 2 |
| Withdrew: Condition under investigation worsened | 40 | 47 |
| Withdrew: Subjective disease progression | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Participants who discontinue treatment prior to progression should continue to be scanned until progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s).
| Months | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| Progression Free Survival: Overall Population (Months) in the Global Cohort | 7.2 (5.5 to 7.4) | 3.6 (2.8 to 3.7) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.
| Percentage of participants | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| PFS rate at 6 months | 51.8 (46.4 to 57.0) | 32.0 (27.0 to 37.0) |
| PFS rate at 9 months | 40.9 (35.6 to 46.1) | 24.4 (19.9 to 29.1) |
| PFS rate at 12 months | 28.5 (23.7 to 33.5) | 18.4 (14.4 to 22.8) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.
| Months | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| Progression Free Survival: Altered Population (Months) in the Global Cohort | 7.3 (5.5 to 9.0) | 3.1 (2.0 to 3.7) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Kaplan-Meier estimate was used.
| Percentage of participants | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| PFS rate at 6 months | 53.4 (45.1 to 60.9) | 29.6 (21.9 to 37.7) |
| PFS rate at 9 months | 42.0 (34.0 to 49.7) | 21.6 (14.9 to 29.1) |
| PFS rate at 12 months | 28.2 (21.2 to 35.6) | 15.8 (10.0 to 22.7) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression.
| Months | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (China Cohort) |
|---|---|---|
| Progression Free Survival: Overall Population (Months) in the China Cohort | 6.9 (5.4 to 9.2) | 2.8 (1.9 to 3.9) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.
| Percentage of participants | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (China Cohort) |
|---|---|---|
| PFS rate at 6 months | 53.9 (41.3 to 65.0) | 24.5 (14.6 to 35.8) |
| PFS rate at 9 months | 40.9 (28.8 to 52.5) | 24.5 (14.6 to 35.8) |
| PFS rate at 12 months | 29.6 (18.6 to 41.4) | 19.1 (10.3 to 29.9) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.
| Months | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| Progression Free Survival: Altered Population (Months) in the China Cohort | 5.7 (3.8 to 8.0) | 1.9 (1.8 to 3.7) |
Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause Kaplan-Meier estimate was used.
| Percentage of participants | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global + China Cohort) |
|---|---|---|
| PFS rate at 6 months | 46.3 (25.1 to 65.1) | 14.3 (3.6 to 32.1) |
| PFS rate at 9 months | 23.1 (8.5 to 42.0) | 14.3 (3.6 to 32.1) |
| PFS rate at 12 months | 6.9 (0.6 to 24.9) | 14.3 (3.6 to 32.1) |
Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from time of signature of the informed consent form, throughout the treatment period and including the 30-day follow-up period after discontinuation of study drug. Only treatment emergent AEs are presented.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capi (Global Cohort) | 4/355 (1.1%) | 57/355 (16.1%) | 334/355 (94.1%) |
| Placebo (Global Cohort) | 1/350 (0.3%) | 28/350 (8%) | 255/350 (72.9%) |
| Capi (China Cohort) | 1/71 (1.4%) | 20/71 (28.2%) | 67/71 (94.4%) |
| Placebo (China Cohort) | 0/62 (0%) | 3/62 (4.8%) | 52/62 (83.9%) |
| Event | Capi (Global Cohort) | Placebo (Global Cohort) | Capi (China Cohort) | Placebo (China Cohort) |
|---|---|---|---|---|
| Rash maculo-papularSkin and subcutaneous tissue disorders | 5/355 | 0/350 | 3/71 | 0/62 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 1/355 | 0/350 | 2/71 | 0/62 |
| VomitingGastrointestinal disorders | 4/355 | 2/350 | 2/71 | 0/62 |
| DiarrhoeaGastrointestinal disorders | 6/355 | 1/350 | 0/71 | 0/62 |
| AnaemiaBlood and lymphatic system disorders | 0/355 | 1/350 | 0/71 | 1/62 |
| Drug-induced liver injuryHepatobiliary disorders | 1/355 | 1/350 | 0/71 | 1/62 |
| Hepatic function abnormalHepatobiliary disorders | 0/355 | 0/350 | 0/71 | 1/62 |
| Pericardial effusionCardiac disorders | 0/355 | 0/350 | 0/71 | 1/62 |
| VertigoEar and labyrinth disorders | 0/355 | 0/350 | 1/71 | 0/62 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/355 | 0/350 | 1/71 | 0/62 |
| Event | Capi (Global Cohort) | Placebo (Global Cohort) | Capi (China Cohort) | Placebo (China Cohort) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 255/355 | 70/350 | 43/71 | 7/62 |
| HyperglycaemiaMetabolism and nutrition disorders | 56/355 | 13/350 | 41/71 | 11/62 |
| NauseaGastrointestinal disorders | 122/355 | 53/350 | 10/71 | 2/62 |
| Alanine aminotransferase increasedInvestigations | 32/355 | 30/350 | 13/71 | 21/62 |
| AnaemiaBlood and lymphatic system disorders | 37/355 | 16/350 | 22/71 | 11/62 |
| RashSkin and subcutaneous tissue disorders | 77/355 | 15/350 | 21/71 | 4/62 |
| Aspartate aminotransferase increasedInvestigations | 33/355 | 33/350 | 10/71 | 18/62 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 52/355 | 9/350 | 18/71 | 2/62 |
| HypokalaemiaMetabolism and nutrition disorders | 15/355 | 2/350 | 18/71 | 6/62 |
| Weight decreasedInvestigations | 12/355 | 8/350 | 17/71 | 3/62 |
Full analysis set. 24 participants (16 participants in the capivasertib arm and 8 participants in the placebo arm) were included in both the Global and China cohorts.
| Age, Continuous(years) | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global Cohort + China Cohort ) | Total |
|---|---|---|---|
| Global cohort | 58.6 ± 11.25 | 57.4 ± 11.91 | 58.0 ± 11.59 |
| China cohort | 54.7 ± 10.66 | 55.0 ± 10.60 | 54.8 ± 10.59 |
| Age, Customized(Participants) | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global Cohort + China Cohort ) | Total |
|---|---|---|---|
| Global cohort — <50 years | 76 | 99 | 175 |
| Global cohort — >=50-<65 years | 164 | 152 | 316 |
| Global cohort — >=65-<75 years | 91 | 76 | 167 |
| Global cohort — >=75 years | 24 | 26 | 50 |
| China cohort — <50 years | 19 | 24 | 43 |
| China cohort — >=50-<65 years | 39 | 21 | 60 |
| China cohort — >=65-<75 years | 12 | 18 | 30 |
| China cohort — >=75 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global Cohort + China Cohort ) | Total |
|---|---|---|---|
| Global cohort — Female | 352 | 349 | 701 |
| Global cohort — Male | 3 | 4 | 7 |
| China cohort — Female | 71 | 62 | 133 |
| China cohort — Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global Cohort + China Cohort ) | Total |
|---|---|---|---|
| Global cohort — Hispanic or Latino | 31 | 31 | 62 |
| Global cohort — Not Hispanic or Latino | 323 | 322 | 645 |
| Global cohort — Unknown or Not Reported | 1 | 0 | 1 |
| China cohort — Hispanic or Latino | 0 | 0 | 0 |
| China cohort — Not Hispanic or Latino | 69 | 61 | 130 |
| China cohort — Unknown or Not Reported | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Capivasertib + Fulvestrant (Global + China Cohort) | Placebo + Fulvestrant (Global Cohort + China Cohort ) | Total |
|---|---|---|---|
| Global cohort — American Indian or Alaska Native | 2 | 2 | 4 |
| Global cohort — Asian | 95 | 94 | 189 |
| Global cohort — Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Global cohort — Black or African American | 4 | 4 | 8 |
| Global cohort — White | 201 | 206 | 407 |
| Global cohort — More than one race | 0 | 0 | 0 |
| Global cohort — Unknown or Not Reported | 52 | 47 | 99 |
| China cohort — American Indian or Alaska Native | 0 | 0 | 0 |
| China cohort — Asian | 69 | 61 | 130 |
| China cohort — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| China cohort — Black or African American | 0 | 0 | 0 |
| China cohort — White | 0 | 0 | 0 |
| China cohort — More than one race | 0 | 0 | 0 |
| China cohort — Unknown or Not Reported | 2 | 2 | 4 |
Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2020 to primary completion in May 2023, 36 months.
Results were first posted in Oct 2025, 2 years 5 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capivasertib